ALKERAN 50 MG — DIN 02087286
MELPHALAN (MELPHALAN HYDROCHLORIDE) : 50 MG BUFFER SOLUTION : 10 ML · ASPEN PHARMACARE CANADA INC. · KIT ; POWDER FOR SOLUTION ; SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is ALKERAN?
ALKERAN 50 MG contains MELPHALAN (MELPHALAN HYDROCHLORIDE) : 50 MG BUFFER SOLUTION : 10 ML. It is listed in the Health Canada Drug Product Database under DIN 02087286, held by ASPEN PHARMACARE CANADA INC., supplied as KIT ; POWDER FOR SOLUTION ; SOLUTION for INTRA-ARTERIAL ; INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 19-Jun-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ALKERAN used for?
Palliative treatment of multiple myeloma and nonresectable epithelial carcinoma of the ovary. Adjuvant to surgery for malignant melanoma (via isolated limb perfusion).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Melphalan cost around the world?
Melphalan is listed on 8 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Iceland publishes a max wholesale. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 4 | 6 | SAR███.██ |
| Greece | producer price (ex-factory) | 3 | 3 | EUR███.██ |
| Morocco | PPV (public price) | 2 | 3 | MAD███.██ |
| Romania | max producer price | 3 | 3 | RON███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| Iceland | max wholesale | 1 | 2 | ISK███.██ |
| Australia | ex-manufacturer | 1 | 1 | AUD███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
21 pack listings across 17 brand entries and 8 price bases, refreshed 08 Sep 2026. Ranges span every Melphalan pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Melphalan in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
7 holders have a Canadian DIN containing Melphalan, across 8 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ASPEN PHARMACARE CANADA INC. | 2 | 2 | ALKERAN | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 1 | 1 | MELPHALAN FOR INJECTION | Sourceable in Canada |
| TARO PHARMACEUTICALS INC | 1 | 1 | TARO-MELPHALAN | Sourceable in Canada |
| APOTEX INC | 1 | 0 | MELPHALAN FOR INJECTION | No marketed DIN |
| AURO PHARMA INC | 1 | 0 | MELPHALAN FOR INJECTION | No marketed DIN |
| EUGIA PHARMA INC. | 1 | 0 | MELPHALAN FOR INJECTION | No marketed DIN |
| JUNO PHARMACEUTICALS CORP. | 1 | 0 | MELPHALAN FOR INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 50 MG |
|---|---|
| Dosage form | KIT ; POWDER FOR SOLUTION ; SOLUTION |
| Route | INTRA-ARTERIAL ; INTRAVENOUS |
| Pack configuration (monograph) | Tablets: Bottles of 50. Injection: 2-component pack (50 mg vial freeze-dried powder and 10 mL vial solvent-diluent). |
| Storage | Injection: Reconstituted solution stable for 2 hours at 30°C; do not refrigerate. Diluted solution (0.1-0.45 mg/mL) stable for 50 mins at 30°C or 3 hours at 20°C. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Melphalan |
|---|---|
| ATC code | L01AA03 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02087286 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2087286 |
| Brand name | ALKERAN |
| Generic / active ingredient | MELPHALAN (MELPHALAN HYDROCHLORIDE) : 50 MG BUFFER SOLUTION : 10 ML |
| Market authorization holder | ASPEN PHARMACARE CANADA INC. |
| Health Canada schedule | Prescription |
| ATC code | L01AA03 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01AA |
| Current status | MARKETED |
| Status date | 19-Jun-2017 |
| Original market date | 1995-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Oral: 6 mg daily initially, adjusted based on blood counts. IV: 16 mg/m2 infused over 15-90 mins. Intra-arterial: 1.0-1.5 mg/kg via hyperthermic isolated limb perfusion.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to melphalan; prior resistance; cross-sensitivity with chlorambucil; recent radiotherapy or other chemotherapy; depressed neutrophil/platelet counts; breast-feeding.
Warnings and precautions
Serious warnings: Hypersensitivity/anaphylaxis, bone marrow suppression, pulmonary toxicity, infertility, secondary malignancies, mutagenicity, and teratogenicity.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 8 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALKERAN | 2 MG | TABLET | ASPEN PHARMACARE CANADA INC. | MARKETED | 00004715 |
| MELPHALAN FOR INJECTION | 50 MG | SOLUTION ; POWDER FOR SOLUTION ; KIT | MARCAN PHARMACEUTICALS INC | MARKETED | 02473348 |
| TARO-MELPHALAN | 10 ML | KIT ; POWDER FOR SOLUTION | TARO PHARMACEUTICALS INC | MARKETED | 02480026 |
| MELPHALAN FOR INJECTION | 10 ML | SOLUTION ; POWDER FOR SOLUTION ; KIT | APOTEX INC | DORMANT | 02468921 |
| MELPHALAN FOR INJECTION | 50 MG | KIT ; POWDER FOR SOLUTION | AURO PHARMA INC | APPROVED | 02508214 |
| MELPHALAN FOR INJECTION | 50 MG | KIT ; POWDER FOR SOLUTION | JUNO PHARMACEUTICALS CORP. | CANCELLED PRE MARKET | 02526077 |
| MELPHALAN FOR INJECTION | 50 MG | KIT ; POWDER FOR SOLUTION | EUGIA PHARMA INC. | APPROVED | 02537389 |
2 · Same class — other molecules in ATC L01AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Cyclophosphamide | CYCLOPHOSPHAMIDE FOR INJECTION · CYCLOPHOSPHAMIDE FOR INJECTION USP · CYTOXAN PWS FOR INJ 1000MG/VIAL · CYTOXAN PWS FOR INJ 2000MG/VIAL · +10 more | 28 | 12 | Yes |
| Bendamustine | BENDAMUSTINE HYDROCHLORIDE FOR INJECTION · BENVYON · ESAMUZE · NAT-BENDAMUSTINE · +1 more | 18 | 11 | Yes |
| Melphalan | ALKERAN · MELPHALAN FOR INJECTION · TARO-MELPHALAN | 8 | 4 | Yes |
| Ifosfamide | IFEX · IFEX PWS 1GM/VIAL · IFEX PWS 2G/VIAL · IFEX PWS 3GM/VIAL · +1 more | 7 | 2 | Yes |
| Chlormethine | LEDAGA · MUSTARGEN | 2 | 1 | Yes |
| Chlorambucil | LEUKERAN | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01AX | Dacarbazine · Temozolomide | 42 | 26 |
| L01AC | Thiotepa | 9 | 6 |
| L01AB | Busulfan · Treosulfan | 10 | 4 |
| L01AD | Carmustine · Lomustine · Streptozocin | 8 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ALKERAN called?
The same molecule, Melphalan, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Melphalan Hydrochloride TBM | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.